Testing the Role for Anti-fungal Therapy in Improving the Response to Medicine for Crohn's Disease
The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to or are undergoing standard of care treatment with an IL-23 therapy for their Crohn's disease.

The main question it aims to assess is will patient response to IL-23 therapies improve when simultaneously treated with fluconazole.
- EligibilityCriteria: Inclusion Criteria:  Patients at least 18 years old Patients with mild to moderate Crohn's disease as defined by CDAI score of 150-450  On stable dosing of any therapy for at least 4 weeks prior to treatment initiation. Including:  Steroids (9 mg or less of budesonide, 20 mg or less of prednisone) Mesalamines Immunomodulators Biologics Other medications for IBD (inflammatory bowel disease)  Exclusion Criteria:  Antibiotic usage within one month prior to initiation of blinded fluconazole treatment Antifungal usage within one month prior to initiation of blinded fluconazole treatment Known allergy to fluconazole Patients with known hepatic disease or cirrhosis Patients taking medications known to interact with fluconazole and cause serious adverse events, including but not limited to death, cardiac events, serious cardiac dysrhythmias, and prolongation of QTc Pregnant or lactating women Severe Crohn's disease defined by a PRO-2 (2-item patient-reported outcome) score ≥ 34 or imminent need for surgery, or deemed not medically fit by physician Patient with symptomatic stricturing Patient with pouchitis or an ostomy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult